Neuralia TMS Delivers Advanced TMS Therapy for OCD Treatment

Australia, 17th Mar 2026 - Neuralia TMS, a leader in non-invasive neurological treatments, has announced an expansion of its services to include transcranial Direct Current Stimulation (tDCS), an at-home neuromodulation therapy, as well as pharmacogenetic testing to optimise treatment outcomes. Known for its expertise in Transcranial Magnetic Stimulation (TMS) therapy, Neuralia TMS continues to provide evidence-based, drug-free treatments for individuals experiencing conditions such as depression, anxiety, PTSD, obsessive-compulsive disorder (OCD), chronic pain, and Parkinsons disease.

Dr Shanek Wick, Medical Director at Neuralia TMS, provided insight into the company's latest offerings: The integration of transcranial Direct Current Stimulation (tDCS) into the treatment portfolio reflects a commitment to exploring advanced, personalised approaches to neuromodulation therapy. tDCS provides patients with a flexible, at-home option that complements the clinical applications of TMS therapy, contributing to enhanced mental health and overall wellness.

TMS therapy, a proven method for treating conditions like depression, is a cornerstone of Neuralia TMS's services. The addition of tDCS expands the available treatment options, responding to growing demand for non-invasive and patient-centred therapies. tDCS works by applying a low electrical current to targeted brain areas, helping to modulate brain activity and support mental well-being. Unlike TMS, which is administered in a clinical setting, tDCS offers patients the convenience of managing their treatment from home, thereby broadening the accessibility of these therapies.

Pharmacogenetic testing is another important development within Neuralia TMSs comprehensive treatment approach. By analysing patients genetic profiles, healthcare providers can tailor treatments to meet individual needs. This personalised strategy enhances the likelihood of positive therapeutic responses while minimising the potential for adverse side effects.

Dr Wick shared further thoughts on the future direction of the company: As the field of neuromodulation continues to evolve, Neuralia TMS remains focused on staying at the forefront of emerging technologies. The organisation is committed to exploring innovative methods that can further improve patient care, with an emphasis on expanding access to non-invasive treatments and making personalised care a standard practice in mental health and neurological therapy.

Neuralia TMS has long been recognised for its dedication to delivering high-quality care. Its multidisciplinary team works closely with patients to create individualised treatment plans that address the full spectrum of mental health and neurological challenges. The recent integration of tDCS and pharmacogenetic testing further establishes Neuralia TMS as a leader in the field, providing patients with a more extensive range of options for managing both mental health and neurological disorders.

These advancements reflect Neuralia TMS's mission to offer a patient-centred approach to mental health care. By utilising the latest developments in non-invasive therapies, Neuralia TMS continues to improve the quality of life for individuals facing complex conditions.

For additional information about Neuralia TMS and its services, including TMS for OCD, or to schedule a consultation, individuals can contact Neuralia TMS directly. The clinic can be reached by phone at 03 6230 3996 or via email at info@neuralia.com.au. Neuralia TMS is dedicated to providing advanced TMS treatments tailored to address various conditions, including obsessive-compulsive disorder (OCD).

Contact Details

Organization: Neuralia TMS

Contact Person: Dr Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: Send Email [https://dashboard.kingnewswire.com/release-contact/42691]

Contact Number: +61862303996

Country: Australia

Release Id: 17032642691

The post Neuralia TMS Delivers Advanced TMS Therapy for OCD Treatment appeared first on King Newswire. This content is provided by a third-party source. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the 'Media Contact' section above.

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. king Newswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact support@kingnewswire.com

This release was published on openPR.